Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail
Zacks Investment Research | Mar 24, 2021 01:24AM ET
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN announced that its phase III outcomes trial on REGEN-COV (casirivimab with imdevimab) in high-risk non-hospitalized COVID-19 patients was successful.
The study evaluated the company’s investigational cocktail antibody, REGEN-COV, in infected non-hospitalized patients (n=4,567).
The study met its primary endpoint, showing that the investigational REGEN-COV significantly reduced the risk of hospitalization or death by 70% (1,200 mg intravenous [IV]) and 71% (2,400 mg IV) compared to placebo. REGEN-COV also met all secondary endpoints in the phase III outcomes trial, including the ability to reduce symptom duration.
Separately, a companion dose-ranging phase II study of 803 outpatient COVID-19 patients was conducted to evaluate the antiviral effect of several different REGEN-COV doses (IV: 2,400 mg, 1,200 mg, 600 mg and 300 mg; SC: 1,200 mg and 600 mg). All tested doses met the primary endpoint, rapidly and significantly reducing patients' viral load. Each dose demonstrated similar efficacy, including the lowest doses tested (IV: 300 mg; SC: 600 mg).
Based on these encouraging data, Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to the Emergency Use Authorization.
These phase III data will also form the basis for a full Biologics License Application.
We remind investors that REGEN-COV received an EUA from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in adults as well as pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization.
Regeneron’s shares have gained 3.8% in the past year compared with the industry ’s growth of 18.5%.
Data published earlier also showed that the REGEN-COV antibody cocktail is effective against the SARS-CoV-2 variants.
Get The News You Want
Regeneron has a collaboration agreement with Roche RHHBY (OTC:RHHBY) for REGEN-COV outside the United States.
Given the alarming levels of the spread and severity of the pandemic, quite a few pharma/biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective enough to treat the infected patients. The emerging new strains pose a greater threat.
Earlier, Vir Biotechnology (NASDAQ:VIR), Inc. GSK announced that an Independent Data Monitoring Committee (IDMC) has recommended that its late-stage study evaluating VIR-7831 (GSK4182136) as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization should pause enrollment due to evidence of profound efficacy.
Regeneron currently carries a Zacks Rank #3 (Hold). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.